Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis

Journal of Infectious Diseases

Volumn 195, Issue 12, 2007, Pages 1846-1851

  Arevalo, Jorge ^a,b   Ramirez, Luis ^a   Adaui, Vanessa ^a   Zimic, Mirko ^b   Tulliano, Gianfranco ^a   Miranda Verástegui, César ^a   Lazo, Marcela ^a   Loayza Muro, Raúl ^b   De Doncker, Simonne ^c   Maurer, Anne ^d   Chappuis, Francois ^d   Dujardin, Jean Claude ^c   Llanos Cuentas, Alejandro ^a  

^a INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^b UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTIMONY; IMIQUIMOD; MEGLUMINE ANTIMONATE;

ADULT; ARTICLE; CLINICAL FEATURE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HUMAN; LEISHMANIA; LEISHMANIA BRAZILIENSIS; LEISHMANIA LAINSONI; LEISHMANIA MEXICANA; LEISHMANIA PERUVIANA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONHUMAN; PARASITE IDENTIFICATION; PARASITE ISOLATION; PERU; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SKIN LEISHMANIASIS; SOUTH AND CENTRAL AMERICA; STATISTICAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; ANTIMONY; ANTIPROTOZOAL AGENTS; GEOGRAPHY; HUMANS; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; PERU; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SPECIES SPECIFICITY; TREATMENT FAILURE;

EID: 34249885063     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/518041     Document Type: Article

References (25)

1. Silveira FT, Lainson R, Corbett CE. Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil: a review. Mem Inst Oswaldo Cruz 2004; 99:239-51.
2. Alvar J, Croft S, Olliaro P. Chemotherapy in the treatment and control of leishmaniasis. Adv Parasitol 2006; 61:223-74.
3. Lucas CM, Franke ED, Cachay MI, et al. Geographic distribution and clinical description of leishmaniasis cases in Peru. Am J Trop Med Hyg 1998; 59:312-7.
4. Reiner NE, Lo R, Llanos-Cuentas A, Guerra H, Button LL, McMaster WR. Genetic heterogeneity in Peruvian Leishmania isolates. Am J Trop Med Hyg 1989; 41:416-21.
5. Arana M, Evans DA, Zolessi A, Cuentas AL, Arevalo J. Biochemical characterization of Leishmania (Viannia) braziliensis and Leishmania (Viannia) peruviana by isoenzyme electrophoresis. Trans R Soc Trop Med Hyg 1990; 84:526-9.
6. Davies CR, Llanos-Cuentas EA, Sharp SJ, et al. Cutaneous leishmaniasis in the Peruvian Andes: factors associated with variability in clinical symptoms, response to treatment, and parasite isolation rate. Clin Infect Dis 1997; 25:302-10.
7. Llanos-Cuentas EA. Risk factors associated with the transmission of Andean cutaneous leishmaniasis [PhD thesis). London: University of London, 1993.
8. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 2001; 95:239-43.
9. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19:111-26.
10. Bermudez H, Rojas E, Garcia L, et al. Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia. Ann Trop Med Parasitol 2006; 100:591-600.
11. Oliveira-Neto MP, Schubach A, Mattos M, Goncalves-Costa SC, Pirmez C. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years). Am J Trop Med Hyg 1997; 57:651-5.
12. Palacios R, Osorio LE, Grajalew LF, Ochoa MT. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. Am J Trop Med Hyg 2001; 64:187-93.
13. World Health Organization. The leishmaniases: report of a WHO expert committee. World Health Organ Tech Rep Ser 1984; 701:1-140.
14. Tobie EJ, Von Brand T, Mehlman B. Cultural and physiological observations on Trypanosoma rhodesiense and Trypanosoma gambiense. J Parasitol 1950; 36:48-54.
15. Garcia AL, Kindt A, Quispe-Tintaya KW, et al. American tegumentary leishmaniasis: antigen-gene polymorphism, taxonomy and clinical pleomorphism. Infect Genet Evol 2005; 5:109-16.
16. Victoir K, De Doncker S, Cabrera L, et al. Direct identification of Leishmania species in biopsies from patients with American tegumentary leishmaniasis. Trans R Soc Trop Med Hyg 2003; 97:80-7.
17. Garcia L, Kindt A, Bermudez H, et al. Culture-independent species typing of neotropical Leishmania for clinical validation of a PCR-based assay targeting heat shock protein 70 genes. J Clin Microbiol 2004; 42:2294-7.
18. Romero GA, Guerra MV, Paes MG, Macedo VO. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L.(V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am J Trop Med Hyg 2001; 65:456-65.
19. Navin TR, Arana BA, Arana FE, Berman JD, Chajon JF. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992; 165:528-34.
20. Soto J, Arana BA, Toledo J, et al. Miltefosine for New World cutaneous leishmaniasis. Clin Infect Dis 2004; 38:1266-72.
21. Croft SL. Monitoring drug resistance in leishmaniasis. Trop Med Int Health 2001; 6:899-905.
22. Allen S, Neal RA. The in vitro susceptibility of macrophages infected with amastigotes of Leishmania spp. to pentavalent antimonial drugs and other compounds with special relevance to cutaneous isolates. In: Hart DT, ed. Leishmaniasis. New York: Plenum Press, 1989:711-20.
23. Yardley V, Ortuno N, Llanos-Cuentas A, et al. American tegumentary leishmaniasis: is antimonial treatment outcome related to parasite drug susceptibility? J Infect Dis 2006; 194:1168-75.
24. Rotureau B, Joubert M, Clyti E, Djossou F, Carme B. Leishmaniasis among gold miners, French Guiana. Emerg Infect Dis 2006; 12:1169-70.
25. Mauricio IL, Yeo M, Baghaei M, et al. Towards multilocus sequence typing of the Leishmania donovani complex: resolving genotypes and haplotypes for five polymorphic metabolic enzymes (ASAT, GP1, NH1, NH2, PGD). Int J Parasitol 2006; 36:757-69.